EASD 2026: Regeneron’s muscle preserver shows benefit at lower doses
The COURAGE data sets Regeneron up to run a further Phase II trial of the muscle preserver in older patients.
The COURAGE data sets Regeneron up to run a further Phase II trial of the muscle preserver in older patients.